▎药明康德内容团队编辑
▲Omega公司的表观遗传学调控平台(图片来源:Omega公司官网)
参考资料:
[1] OMEGA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR OTX-2002, FIRST OMEGA EPIGENOMIC CONTROLLER, FOR MYC DRIVEN HEPATOCELLULAR CARCINOMA. Retrieved July 15, 2022 from https://ir.omegatherapeutics.com/news-releases/news-release-details/omega-therapeutics-announces-fda-clearance-ind-application-otx
[2] Modulation of the MYC Oncogene Using Programmable mRNA Therapeutics as a Novel Therapy for Hepatocellular Carcinoma. William Senapedis, Kayleigh Gallagher, Elmer Figueroa, Jeremiah Farelli, Robert Lyng, Charles O’Donnell, Joseph Newman, Thomas McCauley. Retrieved July 15, 2022 from https://omegatherapeutics.com/wp-content/uploads/2022/06/Modulation-of-the-MYC-Oncogene-Using-Programmable-mRNA-Therapeutics-as-a-Novel-Therapy-for-Hepatocellular-Carcinoma.pdf
[3] Novel Epigenetic Targeting of the MYC Oncogene for the Treatment of NSCLC Using Programmable mRNA Therapeutics. Defne Yarar, Eugine Lee, Houda Belaghzal, Kai-Yuan Chen, Cameron Vergato, Stephen Siecinski, Jeremiah Farelli, Charles O’Donnell, Joseph Newman, Thomas McCauley. Retrieved July 15, 2022 from https://omegatherapeutics.com/wp-content/uploads/2022/05/NSCLC_ASGCT2022_OmegaTherapeutics.pdf
[4] SELECTIVELY DIRECTING THE HUMAN GENOME TO TREAT & CURE SERIOUS DISEASE. Retrieved July 15, 2022 from https://omegatherapeutics.com/our-science/#igds-as-drug-targets
[5] EPIGENOMIC PROGRAMMING FOR PRECISION GENOMIC CONTROL CORPORATE PRESENTATION June 2022. Retrieved July 15, 2022 from https://ir.omegatherapeutics.com/static-files/19a4ba5b-fc26-46ae-80a1-dd4b56047b94
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新